Reviewing Renalytix (NASDAQ:RNLX) & SomaLogic (NASDAQ:SLGCW)

Renalytix (NASDAQ:RNLX) and SomaLogic (NASDAQ:SLGCW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Renalytix and SomaLogic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0	0	2	0	3.00
SomaLogic	0	0	0	0	N/A

Renalytix presently has a consensus price target of $5.00, indicating a potential upside of 139.23%. Given Renalytix’s higher possible upside, research analysts clearly believe Renalytix is more favorable than SomaLogic.

Profitability

This table compares Renalytix and SomaLogic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Renalytix	-1,375.46%	-255.70%	-122.73%
SomaLogic	N/A	N/A	N/A

Earnings & Valuation

This table compares Renalytix and SomaLogic’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	$3.72 million	26.67	-$45.28 million	($0.66)	-3.17
SomaLogic	$101.39 million	N/A	N/A	N/A	N/A

SomaLogic has higher revenue and earnings than Renalytix.

Institutional & Insider Ownership

7.5% of Renalytix shares are owned by institutional investors. 21.6% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

About SomaLogic

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.